课题基金 / 基金详情

POLY MVA UTILIZED AS NEUROPROTEIN IN CHRONIC HYPERTENSION

POLY MVA UTILIZED AS NEUROPROTEIN IN CHRONIC HYPERTENSION
聚 MVA 作为神经蛋白用于治疗慢性高血压
批准号:
7375385
负责人:
CANDICE J PERKINS
金额:
$0.73万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

CANDICE J PERKINS的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得了主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。一些有高血压史的人会出现大脑深部血管硬化和血流减少。这导致氧气输送减少的区域,然后导致能量供应减少和可能的脑细胞死亡。这种情况被称为“小血管病”(SVD)。目前没有FDA批准的治疗这种疾病的方法。我们在斯托尼布鲁克一直在研究的影响,膳食补充剂,聚MVA,作为一种保护对小血管疾病。这种补充剂作为一种“能量提升”;它有能力将能量转移到细胞。我们相信这可以防止脆弱区域的细胞死亡。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Some people with a history of high blood pressure develop hardening and reduced flow in the deep blood vessel of the brain. This results in areas of decreased oxygen delivery, which then results in decreased energy supply and possible brain cell death. This condition is called " Small Vessel Disease" (SVD) . There is no current FDA-approved treatment for this condition. We at Stony Brook have been studying the effects of a dietary supplement , Poly-MVA, as a protection against Small Vessel Disease. This supplement acts as an "energy boost" ; it has the ability to transfer energy to cells. We believe this may prevent cell death in vunerable areas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DESSTINI-DOSE ESCALATION SAFETY STUDY IN NORMAL INDIVIDUALS TAKING POLYMVA
AN OPEN-LABEL, PILOT STUDY OF SAFETY AND TOLERABILITY
TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZEIMER'S DISEASE
POLY MVA UTILIZED AS NEUROPROTEIN IN CHRONIC HYPERTENSION
国内基金
海外基金
加减麦门冬汤干预肺部菌群差异代谢物4-MVA表达诱导巨噬细胞极化调控炎症修复急性肺损伤的机理
  • 批准号:
    2026JJ81044
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    高强
  • 依托单位:
基于靶点识别-动态互作-功能验证体系的盐酸小檗碱调控MVA代谢网络的抗NSCLC治疗耐药分子机制研究
  • 批准号:
    JCZRLH202601045
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
基于MVA/TLR4互作网络的香菇多糖—甲羟戊酸抑制剂组合佐剂协同增效机制研究
  • 批准号:
    32573417
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2025
  • 负责人:
    刘振广
  • 依托单位:
通过调控MVA/HipPO通路促进肠道干细胞再生功能改善肠道GVHD的机制研究